Tidal Investments LLC Has $4.18 Million Holdings in Artivion, Inc. (NYSE:AORT)

Tidal Investments LLC lifted its holdings in shares of Artivion, Inc. (NYSE:AORT) by 602.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 157,002 shares of the company’s stock after purchasing an additional 134,642 shares during the quarter. Tidal Investments LLC owned 0.37% of Artivion worth $4,179,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AORT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Artivion by 58.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after purchasing an additional 125,668 shares during the period. Centiva Capital LP bought a new stake in shares of Artivion during the 3rd quarter worth approximately $565,000. Sio Capital Management LLC acquired a new stake in shares of Artivion during the 3rd quarter worth approximately $3,226,000. First Eagle Investment Management LLC increased its stake in Artivion by 4.9% in the second quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock valued at $15,342,000 after acquiring an additional 27,906 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in Artivion by 543.0% during the third quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company’s stock valued at $761,000 after purchasing an additional 24,130 shares in the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Artivion news, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 8.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jean F. Holloway sold 8,070 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the transaction, the senior vice president now owns 153,862 shares in the company, valued at $4,634,323.44. This represents a 4.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,447 shares of company stock valued at $925,424 in the last ninety days. 8.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AORT. Oppenheimer lifted their target price on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of Artivion in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $34.00 price objective on shares of Artivion in a research note on Monday, December 9th. Finally, Stifel Nicolaus raised their target price on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, September 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.80.

Artivion Stock Down 1.7 %

Shares of NYSE AORT opened at $28.99 on Friday. The company’s 50 day moving average price is $27.70 and its 200-day moving average price is $26.20. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion, Inc. has a 52-week low of $16.48 and a 52-week high of $30.45. The company has a market capitalization of $1.22 billion, a P/E ratio of -1,449.25 and a beta of 1.75.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.